A phase 2 study to examine the efficacy and safety of long-term use of RTU glucagon in a broader range of T1D and T2D patients that exercise at least twice per week
Latest Information Update: 11 Aug 2021
Price :
$35 *
At a glance
- Drugs Glucagon (Primary)
- Indications Exercise-induced hypoglycaemia
- Focus Therapeutic Use
- Sponsors XERIS Pharmaceuticals
- 11 Aug 2021 New trial record
- 05 Aug 2021 According to a Xeris Pharmaceuticals media release, based on FDA feedback, the company anticipates initiating this study in the first quarter of 2022.